Over the past few years, substantial advances have been made in understanding the
pathogenesis, evolution, and complexity of mast cell neoplasms. New diagnostic and …

Mastocytosis is a term used to denote a heterogeneous group of conditions defined by the
expansion and accumulation of clonal (neoplastic) tissue mast cells in various organs. The …

Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT
D816V mutation and associated with poor survival. This phase 1 study (NCT02561988) …

Background Advanced systemic mastocytosis comprises rare hematologic neoplasms that
are associated with a poor prognosis and lack effective treatment options. The multikinase …

Overview Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast
cells (MCs) in extra‐cutaneous organs. Diagnosis The major criterion is presence of …

Systemic mastocytosis (SM) has greatly benefited from the broad application of precision
medicine techniques to hematolymphoid neoplasms. Sensitive detection of the recurrent KIT …

Mast cell activation is common and possibly necessary for maintenance of survival.
Disordered mast cell activation occurs when mast cells are pathologically overproduced or if …

Mast cell activation syndromes (MCASs) are defined by systemic severe and recurrent mast
cell activation, usually in form of anaphylaxis, a substantial, event-related increase of the …

Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor
overall survival (OS). This study (NCT04695431) compared clinical outcomes between …

Patients with clonal mast cell activation syndromes (MCAS) including cutaneous and
systemic mastocytosis (SM) may present with symptoms of mast cell activation, but in …